Refining immunotherapy approvals

Clinical Cancer Research

Volumn 23, Issue 17, 2017, Pages 4948-4949

  Bates, Susan E ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BLOCKING ANTIBODY; DURVALUMAB; GILVETMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; DRUG APPROVAL; DRUG RESPONSE; EDITORIAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; IMMUNOTHERAPY;

DRUG APPROVAL; IMMUNOTHERAPY;

EID: 85029507082     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-2025     Document Type: Editorial

References (4)

1. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007; 13(18 Pt 1):5271-9.
2. Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Advancing clinical trials to streamline drug development. Clin Cancer Res 2015; 21:4527-35.
3. Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol 2017; 44:3-7.
4. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23:1920-8.